NCT01108055 - Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

January 31, 2015

Study Completion Date

July 31, 2015

Conditions

Bladder CancerBladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable

Interventions

DRUG

Pazopanib (GW786034)

Cycle of 28 days. Pazopanib: 800mg/day

DRUG

Paclitaxel

Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15

Trial Locations (2)

48201

Karmanos Cancer Institute, Detroit

94305

Stanford University School of Medicine, Stanford